% | $
Quotes you view appear here for quick access.

Momenta Pharmaceuticals Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • bdover23 bdover23 Dec 10, 2011 10:44 AM Flag

    Q4 earnings

    50-50 split is good but copaxone is less than half of the brand market size of lovenox in the US so less then half the sales potential, with new improved drugs coming out that will even lower the brand size

    I agree an AG may not come out right away but if MNTA sets it sights on more then 50% market share then one will come for sure, teva will also have a few tricks planned since they have seen it all.

    Mylan has been saying they are going to get approval for years and as long as they say it it will hold the stock down, because if teva has not done an AG they will if mylan comes in so it will be a huge overhang

    I agree that copaxone is a big plus but the real stock driver will be a biologic, that is why people are investing copaxone is the last generic non biologic as soon as copaxone gets approved the street will say whats next and next will be pretty far off.

    This is where MGT let us down!!

17.97+0.19(+1.07%)Nov 25 4:00 PMEST